Terumo and UMCU strengthen their partnership to develop solutions in Interventional Oncology
LEUVEN, Belgium, July 20, 2021 /PRNewswire/ -- Terumo Europe and University Medical Center Utrecht (UMC Utrecht) announced today that they signed a Memorandum of Understanding (MoU) to recognize the longstanding partnership in the field of oncology. In the past years, both parties have successful...
Terumo Introduces New AZUR™ Vascular Plug and PG Pro™ Peripheral Microcatheter Embolization System
SOMERSET, N.J., July 14, 2021 /PRNewswire/ -- Terumo Medical Corporation (TMC) has announced today the introduction of its AZUR™ Vascular Plug, the first and only plug compatible with a microcatheter to occlude arteries up to 8mm in diameter. The newest addition to Terumo's robust embolization po...
Terumo Donates Additional USD 1 Million to Support the COVID-19 Solidarity Response Fund for WHO
TOKYO, May 14, 2021 /PRNewswire/ -- As the world joins together to fight the ongoing battle against the COVID-19 pandemic, Terumo Corporation (TSE: 4543) has announced that the Terumo Group companies will collectively donateUSD 1 million in cash to support the COVID-19 Solidarity Response Fund fo...
Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform
LAKEWOOD, Colo. and BOCA RATON, Fla., April 19, 2021 /PRNewswire/ -- Terumo Blood and Cell Technologies and CSL Plasma today announce a collaboration to deliver a new plasma collection platform at CSL Plasma U.S. collection centers. A clinical trial of the investigational plasmapheresis device ...
Terumo is building a Global Therapeutic Interventional Oncology team to offer more therapeutic solution to cancer patients
LEUVEN, Belgium, April 12, 2021 /PRNewswire/ -- Terumo is proud to announce the launch of its Global Therapeutic Interventional Oncology team as ofApril 1st, 2021. This reflects Terumo's aspiration to be a Global leader in the field of Interventional Oncology by focusing on improving patient's qu...
Terumo Signs a Definitive Agreement to Acquire All Assets of Health Outcomes Sciences, Inc.
TOKYO, Feb. 23, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543), a global leader in medical technology, has signed a definitive agreement to acquire all assets of Health Outcomes Sciences, Inc. (HOS). HOS specializes in predictive analytics and clinical decision support that enable healthcare...
A Novel Drug-Device Combination Product Using Terumo's Automated Injection Device Completes Clinical Study in Japan
TOKYO, Feb. 8, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced the completion of a clinical study inJapan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin). Kyowa Kirin initiated the clinica...
Terumo Enters 100th Anniversary Year
TOKYO, Jan. 5, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) is celebrating its 100th anniversary this year - marking 100 years of 'Contributing to Society through Healthcare' onSeptember 17, 2021. The company has established 'Stride Ahead' as a slogan, to celebrate and connect all Terumo ...
Terumo Acquires Quirem Medical to Enhance Its Interventional Oncology Field
TOKYO and DEVENTER, Netherlands, July 15, 2020 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced it has completed the acquisition of Quirem Medical B.V., aNetherlands-based healthcare startup specializing in the development of next-generation microspheres for Selective Internal Radia...
Medeon Entering Asset Purchase Agreement with Terumo for its Large Bore Vascular Closure System
TAIPEI, , March 5, 2018 /PRNewswire/ -- Medeon Biodesign, Inc. (TPEx: 6499), aTaiwan publicly traded medical device company, is pleased to announce today that it entered into a definitive asset purchase agreement withTokyo -based Terumo Corporation (TSE: 4543) for its large bore vascular closure ...
